Efficacy of treatments for Japanese cedar pollinosis based on guideline -combined treatment ofleukotriene receptor antagonist with H1 receptor antagonists

Efficacy of treatments for Japanese cedar pollinosis based on guideline -combined treatment ofleukotriene receptor antagonist with H1 receptor antagonists - Combined treatment of LTRA with H1RA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009647

Enrollment

100

Registered

2013-06-01

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

intranasal corticosteroid antihistamine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Japanese ceadr pollinosis haveing symptoms at least 2 seasons.

Exclusion criteria

Exclusion criteria: (1) concomitant sinonasal disease that could potentially affect the outcome of the trial (e.g., nasal polyps, rhinosinusitis, nasal septum deviation); (2) concomitant treatment for AR caused by allergens other than Japanese cedar/cypress pollen; (3) rhinitis medicamentosa and non-infectious, non-allergic rhinitis; (4) medication with anti-allergic drugs including H1RA, chromones, glucocorticoids and decongestants within 2 weeks of study initiation; (5) cedar pollen-specific immunotherapy; (6) sinonasal surgery including laser vaporization of inferior turbinates within 6 months;(7) concomittant uncontrolled asthma (8) hypersensitivity to INS and H1RA (9)systemic infection including mycosis; or (10) were pregnant and breastfeeding.

Design outcomes

Primary

Measure	Time frame
Symptoms and QOL	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026